CN111743858A - Pharmaceutical composition of bromfenac sodium - Google Patents
Pharmaceutical composition of bromfenac sodium Download PDFInfo
- Publication number
- CN111743858A CN111743858A CN201910252261.5A CN201910252261A CN111743858A CN 111743858 A CN111743858 A CN 111743858A CN 201910252261 A CN201910252261 A CN 201910252261A CN 111743858 A CN111743858 A CN 111743858A
- Authority
- CN
- China
- Prior art keywords
- sodium
- bromfenac
- percent
- dextran
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention provides a bromfenac sodium pharmaceutical composition, which comprises 0.01-0.5 wt% of bromfenac sodium sesquihydrate and pharmacologically acceptable salts thereof; viscosity modifiers, dextran; 0.01 to 1 percent of the weight percentage; 0.01 to 1 percent of surfactant by weight; 0.01 to 0.5 percent of antioxidant by weight; optionally other pharmacologically acceptable excipients. The invention has the beneficial effects that when the bromfenac sodium eye drops contain dextran 40 or dextran 70, the generation of impurities U-II can be effectively avoided, and the addition of the dextran can also ensure the bacteriostatic effect of benzalkonium chloride, increase the retention time in eyes and improve the drug effect.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to a pharmaceutical composition of bromfenac sodium.
Background
Chemical name of bromfenac sodium: 2-amino-3- (4-bromobenzoyl) phenylacetic acid (sodium) of the formula:
bromfenac sodium is a nonsteroidal anti-inflammatory drug with anti-inflammatory activity. The mechanism of action is to prevent prostaglandin synthesis by inhibiting cyclooxygenase enzymes 1 and 2. The prostate gland is a mediator of some intraocular inflammation, and prostaglandins can disrupt the blood-aqueous humor barrier, vasodilate, increase vascular permeability, leukocytosis, and elevated intraocular pressure.
The bromfenac sodium eye drops were developed by Senju corporation of Japan and marketed in Japan in 2000 under the trade name of ブロナック/eye drop SOLUTION (BRONUCK OPHTHALMIC SOLUTION), and were 5 ml/minute of a 0.1% bromfenac sodium eye SOLUTION (calculated as bromfenac sodium hydrate) twice daily. Marketed in the united states at 3 months 2005 under the trade name xiburrom (twice daily), and again in 2010 under the trade name Bromday (the prescription should be the same as xiburrom, a new once daily dosing regimen). In 2013, doctor-renowned (by ISTA) marketed new prescription 0.07% bromfenac sodium eye drops (PROLENSA, calculated as bromfenac, once a day) in the United states. In recent years, the ophthalmic anti-inflammatory single preparation in China always accounts for about 20% of the dosage of ophthalmic medicines, and the bromfenac sodium eye drops are taken 1 time a day, so that the bromfenac sodium eye drops are convenient to use, high in patient compliance and small in side effect, and therefore have a good market.
Patent CN103379904 (qianshou) discloses a composition which can effectively ensure the bacteriostatic effect and safety of bromfenac sodium; the conventional reduction of the preservation efficiency caused by the non-steroidal compounds and the quaternary ammonium salts is broken through, and benzalkonium chloride is used as a preservative in the bromfenac sodium eye drops; patent 200480000976.3 (qianshou) discloses bromfenac sodium eye drops with tyloxapol as a surfactant, which avoids the decrease of bacteriostatic function caused by the combination of polysorbate 80 and benzalkonium; patent CN1993118B (qianshou) discloses bromfenac sodium eye drops containing organic amine, specifically including organic amine of alkanol amine and amino alkyl sulfonic acid, to improve the permeability of bromfenac in eyes and increase the retention time of effective concentration of drug in eyes, but the organic amine reagent has irritation to eyes.
CN104203224A discloses bromfenac sodium eye drops, which are stabilized by the ratio of benzalkonium chloride to polyoxyethylene sorbitan fatty acid ester; CN105451731A (Shentian) discloses a preparation method of bromfenac sodium eye drops, which comprises bromfenac sodium, benzalkonium bromide and polyoxyethylene sorbitan fatty acid ester, and the bromfenac sodium eye drops are more stable by limiting the dosage proportion of main and auxiliary materials in the prescription;
patent CN104812370A (Bauschelan) discloses a bromfenac sodium preparation with stable preservative efficacy, which limits the use of a nonionic surfactant in bromfenac sodium eye drops, and screens the specific combination of the types of the surfactant and the preservative; CN104523587A discloses a method for reducing the generation of impurity U-II in the preparation by replacing polyvidone with sodium hyaluronate and other thickening agents; CN101313899A (Dezhongwang, 2007) solves the problem of long-term storage stability of the eye drops by adding a cosolvent of hydroxyethyl cellulose.
Through published data and the process of developing bromfenac sodium eye drops, the polysorbate 80 and the benzalkonium chloride serving as a preservative in the original prescription are combined for use, so that the bacteriostatic effect of the benzalkonium chloride can be reduced, and certain safety risk is realized; bromfenac sodium and the thickener povidone tend to produce a polymeric impurity U-II which increases with the time of copying and with the temperature, the content of this impurity in the original product being studied at a near-term of validity being around 3%.
Bacteriostatic agents (also called preservatives) refer to chemical substances that inhibit the growth of microorganisms, and according to rules 1121 of the chinese pharmacopoeia 2015 edition, if the drug itself does not have sufficient bacteriostatic effect, then appropriate bacteriostatic agents should be added according to the formulation characteristics (such as water-soluble formulations) to prevent the drug from deteriorating and causing harm to users due to microbial contamination and reproduction during normal storage or use of the formulation, especially in multi-dose packaged formulations. The benzalkonium chloride is also a bacteriostatic agent, and can damage the normal moistening and repairing functions of human tears on ocular surface tissue cells to cause corneal epithelial damage and dry eye after being used for a long time or in a large dose.
In the process of drug production, bacteriostats cannot be used to replace GMP management in drug production, cannot be used as the only way for reducing microbial contamination of non-sterile preparations, and cannot be used as a means for controlling the biological load of multi-dose packaged preparations before sterilization, all bacteriostats have certain toxicity, and the quantity of bacteriostats in the preparations should be the lowest effective dose.
Disclosure of Invention
The invention aims to provide a bromfenac sodium ophthalmic preparation which has the advantages of easily obtained raw materials, simple process, good stability and high safety.
The technical scheme of the invention is as follows: a pharmaceutical composition of bromfenac sodium comprises
Bromfenac sodium sesquihydrate and pharmacologically acceptable salts thereof;
viscosity modifiers, dextran;
a surfactant;
an antioxidant;
optionally other pharmacologically acceptable excipients.
A pharmaceutical composition of bromfenac sodium comprises
0.01-0.5% of bromfenac sodium sesquihydrate and pharmacologically acceptable salts thereof;
viscosity modifiers, dextran; 0.01 to 1 percent of the weight percentage;
0.01 to 1 percent of surfactant by weight;
0.01 to 0.5 percent of antioxidant by weight;
optionally other pharmacologically acceptable excipients.
The dextran is selected from dextran 40 or dextran 70.
In the bromfenac sodium composition, the surfactant is selected from polysorbate 80, poloxamer and tyloxapol.
In the bromfenac sodium composition, the antioxidant is selected from sodium metabisulfite, sodium sulfite, sodium thiosulfate, ascorbic acid and sodium bisulfite.
The bromfenac sodium composition also comprises a preservative; the preservative is selected from benzalkonium chloride, benzalkonium bromide, benzethonium chloride, benzyl alcohol, chlorobutanol, phenethyl alcohol, sorbic acid, chlorhexidine, nitropropanol, o-phenylphenol, methyl/ethyl/propyl p-hydroxybenzoate, phenol, phenylmercuric acetate/phenyl nitrate, sodium benzoate, beta-phenylethyl alcohol and thimerosal.
In order to obtain better technical effect, the preservative is selected from benzalkonium chloride, methyl p-hydroxybenzoate and ethyl p-hydroxybenzoate.
The bromfenac sodium composition also comprises an osmotic pressure regulator; the osmotic pressure regulator is selected from one or more of sodium chloride, glucose, mannitol, glycerol, xylitol, sorbitol, boric acid and borax;
for better technical effect, the osmotic pressure regulator is selected from sodium chloride, mannitol, boric acid and borax.
The bromfenac sodium composition further comprises a pH regulator, wherein the pH regulator is selected from one or more of sodium hydroxide, calcium hydroxide, sodium citrate, citric acid, hydrochloric acid, phosphoric acid, disodium hydrogen phosphate, sodium dihydrogen phosphate, boric acid and borax;
in order to obtain better technical effect, the pH regulator is selected from boric acid, borax and sodium hydroxide, and the pH is regulated to 8.0-8.6.
The bromfenac sodium composition further comprises a complexing agent, and the complexing agent is selected from edetate disodium.
A pharmaceutical composition of bromfenac sodium comprises
0.01-0.5% of bromfenac sodium sesquihydrate;
dextran 40; 0.01 to 0.5 percent;
0.01 to 1 percent of polysorbate 80;
0.01 to 0.5 percent of sodium sulfite;
0.001-0.01% of benzalkonium chloride;
0.5 to 1.5 percent of boric acid;
0.5 to 1.5 percent of borax;
0.001 to 0.05 percent of edetate disodium;
adjusting the pH value to 8.0-8.6 by using sodium hydroxide;
the balance being water.
A pharmaceutical composition of bromfenac sodium comprises
0.05-0.2% of bromfenac sodium sesquihydrate;
dextran 40; 0.01 to 0.4 percent;
0.05 to 0.5 percent of polysorbate 80;
0.05 to 0.4 percent of sodium sulfite;
benzalkonium chloride 0.002-0.003%;
0.5 to 1.5 percent of boric acid;
0.5 to 1.5 percent of borax;
0.005-0.05% of edetate disodium;
adjusting the pH value to 8.0-8.6 by using sodium hydroxide;
the balance being water.
A pharmaceutical composition of bromfenac sodium comprises
0.1% of bromfenac sodium sesquihydrate;
dextran 40; 0.1 percent;
polysorbate 80, 0.15%;
sodium sulfite, 0.2%;
benzalkonium chloride, 0.003%;
boric acid, 1.1%;
1.1 percent of borax;
disodium edetate, 0.02%;
adjusting the pH value to 8.2-8.4 by using sodium hydroxide;
the balance being water.
The invention has the advantages and positive effects that: through researching physical and chemical properties of a large amount of preparation auxiliary materials and interaction between the preparation auxiliary materials and main components, and then screening for hundreds of times of compositions, the bromfenac sodium eye drops can effectively avoid generation of impurities U-II when containing dextran 40 or dextran 70.
Detailed Description
The invention will now be further described by way of the following examples, which are not intended to limit the scope of the invention in any way. It will be understood by those skilled in the art that equivalent substitutions for the technical features of the present invention, or corresponding modifications, can be made within the scope of the present invention.
Example 1
A pharmaceutical composition of bromfenac sodium, 40ml, comprises
Bromfenac sodium sesquihydrate, 41.4mg
Dextran 40, 40 mg;
polysorbate 80, 60 mg;
sodium sulfite, 80 mg;
benzalkonium chloride 1 mg;
boric acid, 440 mg;
borax, 440 mg;
disodium edetate, 8 mg;
adding water to 40ml
The pH was adjusted to 8.3 with 10% sodium hydroxide.
Example 2 to example 5
Examples 6 to 8
Comparative example 1 to comparative example 2
An eye drop prepared according to the prescription and process of example 2 of CN104523587A is referred to as comparative example 1;
prescription: 5g of bromfenac sodium, 1g of hydroxypropyl methylcellulose, 1g of carbomer, 27.9g of sodium citrate, 52.5g of disodium hydrogen phosphate, 0.2g of methyl paraben, 0.3g of methyl hydroxybenzoate propyl ester, 0.2g of p-hydroxy tert-butyl anisole, 0.3g of propyl gallate, 0.4g of triethanolamine and 0.2g of tryptophan, and the total volume of water for injection is 5000ml, and 1000 pieces are prepared.
An eye drop prepared according to the prescription and process of example 4 of CN104523587A is referred to as comparative example 2;
prescription: bromfenac sodium 5g, molecular weight range 1.2x1068g of sodium hyaluronate, 27.9g of boric acid, 52.5g of borax, benzalkonium bromide and 1g of weight-average molecular weight Mn which is 2.717x105The seed melon polysaccharide sulfate, anhydrous sodium sulfite 0.5g, edetate disodium 0.5g, water for injection added to 5000ml, total 1000 pieces.
Comparative example 3
The prescription of embodiment NGB-10 according to CN104812370A is consistent: bromfenac sodium 0.07%, boric acid 1.4%, sodium borate 0.74%, sodium sulfite 0.2%, EDTA 0.02%, povidone 1.00%, polyquaternium-10.001%, poloxamer 4070.02%, and sodium hydroxide to adjust pH to 7.8.
Comparative example 4
Patent 200480000976.3, example A-04 as comparative example 4, was formulated as:
0.1g of bromfenac sodium, 1.1g of boric acid, 1.1g of borax, 0.003g of benzalkonium chloride, 0.02g of tetrabutyl phenol, 2.0g of polyvinylpyrrolidone (k-30), 0.02g of sodium edetate, water until the volume is 100ml, and sodium hydroxide is used for adjusting the pH value to 8.17.
Comparative example 5
100ml of pharmaceutical composition of bromfenac sodium comprises
Bromfenac sodium sesquihydrate, 80.5mg
Polysorbate 80, 150 mg;
sodium sulfite, 200 mg;
benzalkonium chloride, 3 mg;
propylene glycol, 500 mg;
boric acid, 1100 mg;
borax, 1100 mg;
20mg of edetate disodium;
adding water to 100ml
The pH was adjusted to 8.3 with 10% sodium hydroxide.
Stability test
Long-term stability study of bromfenac sodium eye drops
After being prepared, the bromfenac sodium eye drops are placed in a low-density polyethylene medicinal eye drop bottle in a dark place, long-term stability tests are carried out according to the requirements of pharmacopoeia, and the bromfenac sodium eye drops are stored in the dark and cool places at the temperature of 25 +/-2 ℃ and the humidity of 40% +/-5%.
Examination items:
[ CONTENT ] the bromfenac sodium sesquihydrate should be 90% -110% of the labeled amount.
[ PROPERTIES ] the product is a yellow clear liquid.
The pH value should be 8.0-8.6.
[ RELATED MATERIALS ] the related substances were detected by HPLC using octadecylsilane chemically bonded silica as filler,
using phosphate buffer (pH7.3) -acetonitrile (30:70) as mobile phase, detecting with ultraviolet detector.
[ osmolality ratio ] should be 0.9-1.1.
[ STERILE ] the product should meet the regulations by thin film filtration and legal inspection.
The test results are given in the following table:
detection of bacteriostatic efficacy
According to the bacteriostatic efficacy inspection method of 1121 of the general guidelines of Chinese pharmacopoeia 2015, the bacteriostatic efficacy of the eye drops in the examples and the comparative examples is detected, and as a result, all the eye drops in the examples meet the A standard in the pharmacopoeia standard; in the control examples, only control example 4 met the a standard of the pharmacopoeia standard of the CP2015 bacteriostatic efficacy test, and the remainder either met only the B standard or did not meet the standard of the CP 2015.
Specific data are shown in the following table:
while general embodiments of the present invention have been described in detail, the description is only for the purpose of illustrating the preferred embodiments of the present invention and should not be construed as limiting the scope of the invention. All equivalent changes and modifications made within the scope of the present invention shall fall within the scope of the present invention.
Claims (10)
1. A pharmaceutical composition of bromfenac sodium, characterized in that: comprises that
Bromfenac sodium sesquihydrate and pharmacologically acceptable salts thereof;
viscosity modifiers, dextran;
a surfactant;
an antioxidant;
optionally other pharmacologically acceptable excipients.
2. The pharmaceutical composition of bromfenac sodium according to claim 1, wherein: comprises that
0.01-0.5% of bromfenac sodium sesquihydrate and pharmacologically acceptable salts thereof;
viscosity modifiers, dextran; 0.01 to 1 percent of the weight percentage;
0.01 to 1 percent of surfactant by weight;
0.01 to 0.5 percent of antioxidant by weight;
optionally other pharmacologically acceptable excipients.
3. The pharmaceutical composition of sodium bromfenac according to claim 1 or 2, wherein: the dextran is selected from dextran 40 or dextran 70.
4. The pharmaceutical composition of sodium bromfenac according to claim 1 or 2, wherein: the surfactant is selected from polysorbate 80, poloxamer, and tyloxapol.
5. The pharmaceutical composition of sodium bromfenac according to claim 1 or 2, wherein: the antioxidant is selected from sodium pyrosulfite, sodium sulfite, sodium thiosulfate, ascorbic acid and sodium bisulfite.
6. The pharmaceutical composition of sodium bromfenac according to claim 1 or 2, wherein: also comprises a preservative; the preservative is selected from benzalkonium chloride, benzalkonium bromide, benzethonium chloride, benzyl alcohol, chlorobutanol, phenethyl alcohol, sorbic acid, chlorhexidine, nitropropanol, o-phenylphenol, methyl/ethyl/propyl p-hydroxybenzoate, phenol, phenylmercuric acetate/phenyl nitrate, sodium benzoate, beta-phenylethyl alcohol and thimerosal.
7. The pharmaceutical composition of sodium bromfenac according to claim 1 or 2, wherein: the bromfenac sodium composition also comprises an osmotic pressure regulator; the osmotic pressure regulator is one or more selected from sodium chloride, glucose, mannitol, glycerol, xylitol, sorbitol, boric acid and borax.
8. The pharmaceutical composition of sodium bromfenac according to claim 1 or 2, wherein: the pH regulator is selected from one or more of sodium hydroxide, calcium hydroxide, sodium citrate, citric acid, hydrochloric acid, phosphoric acid, disodium hydrogen phosphate, sodium dihydrogen phosphate, boric acid and borax.
9. A pharmaceutical composition of bromfenac sodium comprises
0.01-0.5% of bromfenac sodium sesquihydrate;
dextran 40 or dextran 70; 0.01 to 0.5 percent;
0.01 to 1 percent of polysorbate 80;
0.01 to 0.5 percent of sodium sulfite;
0.001-0.01% of benzalkonium chloride;
0.5 to 1.5 percent of boric acid;
0.5 to 1.5 percent of borax;
0.001 to 0.05 percent of edetate disodium;
adjusting the pH value to 8.0-8.6 by using sodium hydroxide;
the balance being water.
10. A pharmaceutical composition of bromfenac sodium comprises
0.05-0.2% of bromfenac sodium sesquihydrate;
dextran 40 or dextran 70; 0.01 to 0.4 percent;
0.05 to 0.5 percent of polysorbate 80;
0.05 to 0.4 percent of sodium sulfite;
benzalkonium chloride 0.002-0.003%;
0.5 to 1.5 percent of boric acid;
0.5 to 1.5 percent of borax;
0.005-0.05% of edetate disodium;
adjusting the pH value to 8.0-8.6 by using sodium hydroxide;
the balance being water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910252261.5A CN111743858B (en) | 2019-03-29 | 2019-03-29 | Pharmaceutical composition of bromfenac sodium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910252261.5A CN111743858B (en) | 2019-03-29 | 2019-03-29 | Pharmaceutical composition of bromfenac sodium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111743858A true CN111743858A (en) | 2020-10-09 |
| CN111743858B CN111743858B (en) | 2023-06-27 |
Family
ID=72672556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910252261.5A Active CN111743858B (en) | 2019-03-29 | 2019-03-29 | Pharmaceutical composition of bromfenac sodium |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111743858B (en) |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1823754A (en) * | 2006-03-28 | 2006-08-30 | 卢秀莲 | Sodium bromophenolate eye drops and its preparation method |
| CN1993118A (en) * | 2004-11-05 | 2007-07-04 | 千寿制药株式会社 | Aqueous eye drops with accelerated intraocular migration permeability |
| CN101313899A (en) * | 2007-06-01 | 2008-12-03 | 北京德众万全药物技术开发有限公司 | Medicament composition for eyes containing sodium bromfenac |
| US20100227928A1 (en) * | 2009-03-05 | 2010-09-09 | Kamran Hosseini | Non-steroidal anti-inflammatory ophthalmic compositions |
| CN102283805A (en) * | 2011-06-29 | 2011-12-21 | 扬子江药业集团有限公司 | Method for preparing eye drops containing non-ionic cellulose derivatives |
| US20130023575A1 (en) * | 2011-07-22 | 2013-01-24 | Kamran Hosseini | Compositions and methods for the treatment of ocular surface allergies |
| CN102988278A (en) * | 2011-09-19 | 2013-03-27 | 娄飞 | Bromfenac sodium hydrate eye drops and preparation method thereof |
| CN104523587A (en) * | 2014-12-31 | 2015-04-22 | 辰欣药业股份有限公司 | Bromfenac sodium eye drops and preparation method thereof |
| CN104812370A (en) * | 2012-11-19 | 2015-07-29 | 博士伦公司 | Aqueous liquid composition containing 2-amino-3-(4-bromobenzoyl) phenylacetic acid |
| CN107854469A (en) * | 2016-09-21 | 2018-03-30 | 刘力 | Topical ophthalmic or the husky star medicine of ear or nose use or external preparation for skin and combinations thereof |
| CN108853074A (en) * | 2017-05-10 | 2018-11-23 | 武汉先路医药科技股份有限公司 | A kind of pharmaceutical aqueous eye drops and preparation method thereof containing bromfenac sodium hydrate |
-
2019
- 2019-03-29 CN CN201910252261.5A patent/CN111743858B/en active Active
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1993118A (en) * | 2004-11-05 | 2007-07-04 | 千寿制药株式会社 | Aqueous eye drops with accelerated intraocular migration permeability |
| CN1823754A (en) * | 2006-03-28 | 2006-08-30 | 卢秀莲 | Sodium bromophenolate eye drops and its preparation method |
| CN101313899A (en) * | 2007-06-01 | 2008-12-03 | 北京德众万全药物技术开发有限公司 | Medicament composition for eyes containing sodium bromfenac |
| US20100227928A1 (en) * | 2009-03-05 | 2010-09-09 | Kamran Hosseini | Non-steroidal anti-inflammatory ophthalmic compositions |
| CN102283805A (en) * | 2011-06-29 | 2011-12-21 | 扬子江药业集团有限公司 | Method for preparing eye drops containing non-ionic cellulose derivatives |
| US20130023575A1 (en) * | 2011-07-22 | 2013-01-24 | Kamran Hosseini | Compositions and methods for the treatment of ocular surface allergies |
| CN102988278A (en) * | 2011-09-19 | 2013-03-27 | 娄飞 | Bromfenac sodium hydrate eye drops and preparation method thereof |
| CN104812370A (en) * | 2012-11-19 | 2015-07-29 | 博士伦公司 | Aqueous liquid composition containing 2-amino-3-(4-bromobenzoyl) phenylacetic acid |
| CN104523587A (en) * | 2014-12-31 | 2015-04-22 | 辰欣药业股份有限公司 | Bromfenac sodium eye drops and preparation method thereof |
| CN107854469A (en) * | 2016-09-21 | 2018-03-30 | 刘力 | Topical ophthalmic or the husky star medicine of ear or nose use or external preparation for skin and combinations thereof |
| CN108853074A (en) * | 2017-05-10 | 2018-11-23 | 武汉先路医药科技股份有限公司 | A kind of pharmaceutical aqueous eye drops and preparation method thereof containing bromfenac sodium hydrate |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111743858B (en) | 2023-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6455547B1 (en) | Method for treating pharmaceutical compositions | |
| AU742920B2 (en) | Autoclavable pharmaceutical compositions containing a chelating agent | |
| JP6603785B2 (en) | Aqueous solution containing water-soluble polymer | |
| JP2011508776A (en) | Stable aqueous cyclosporine composition | |
| JP3170619B2 (en) | Planoprofen ophthalmic solution containing organic amine | |
| JP2018177820A (en) | Aqueous ophthalmic composition | |
| US9138481B2 (en) | Cellulosic gel composition with improved viscosity stability | |
| JP2023181428A (en) | Ophthalmic composition | |
| US20030031718A1 (en) | Ophthalmic compositions and use | |
| JP2019006776A (en) | Eye drop containing water-soluble polymer | |
| JP2021130657A (en) | Pharmaceutical product | |
| CN111743858A (en) | Pharmaceutical composition of bromfenac sodium | |
| JP2007277233A (en) | Ophthalmic composition | |
| JP2022157707A (en) | ophthalmic composition | |
| JP6798054B1 (en) | Pharmaceutical products | |
| WO2024034592A1 (en) | Aqueous pharmaceutical composition containing udca or salt thereof | |
| JP2022109891A (en) | Stabilized eye drops containing 4 components | |
| JP2022180426A (en) | Olopatadine-containing aqueous composition | |
| JP2016041749A (en) | Ophthalmic composition for silicone hydrogel contact lens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| CB02 | Change of applicant information |
Address after: 300 457 days north of Xinye Jiujie Street and east of Xinhuan West Road, Dongli District Development Zone, Tianjin Applicant after: Tianjin Pharmaceutical Research Institute Co.,Ltd. Address before: 300 457 days north of Xinye Jiujie Street and east of Xinhuan West Road, Dongli District Development Zone, Tianjin Applicant before: TIANJIN PHARMACEUTICALS Group Corp. |
|
| CB02 | Change of applicant information | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |